Lv25
120 积分 2024-04-19 加入
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
21天前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
27天前
已完结
Atrasentan in Patients with IgA Nephropathy
27天前
已完结
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
1个月前
已完结
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single‐arm study
1个月前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
1个月前
已完结
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
1个月前
已完结
[Consensus on diagnosis and treatment of complement-mediated kidney diseases]
1个月前
已完结
siRNA: Mechanism of action, challenges, and therapeutic approaches
2个月前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
5个月前
已完结
皖公网安备34019202002308
